Compare Cigna Corp (CI) vs Colgate-Palmolive Company (CL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Colgate-Palmolive Company — how do they compare? Cigna Corp trades at $272.72 (market cap $73.56B), while Colgate-Palmolive Company trades at $92.43 (market cap $73.59B). The key difference: Cigna Corp and Colgate-Palmolive Company are close in size by market cap, and Colgate-Palmolive Company pays the higher dividend (2.3%). Which is the better fit depends on your goals.
| CI | CL | |
|---|---|---|
Market Cap | $73.56B | $73.59B |
Sector | Health | Consumer Staples |
52-Week High | $311.00 | $99.14 |
52-Week Low | $244.41 | $74.98 |
Enterprise Value | $98.27B | $80.07B |
Dividend Yield | 2.24% | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $278.15, showing slight daily weakness but maintaining a strong fundamental profile with consistent earnings beats. The stock appears undervalued with a P/E of 11.51 and P/S of 0.26, while technical indicators show bearish momentum near key support at $271. Recent Q2 2026 results exceeded expectations with EPS of $7.78 versus $7.60 estimates, driving management's raised full-year guidance.
Cigna presents a compelling value opportunity with analyst consensus pointing to 22% upside to the $338.90 price target. However, near-term technical pressure and competitive healthcare margins require monitoring. The company's stable dividend payments and institutional accumulation support long-term confidence despite current bearish technical signals.
Colgate-Palmolive (CL) trades at $92.54, down 0.65% on the day, with neutral technical signals and strong fundamentals. The company reported Q2 2026 EPS of $0.99, beating estimates, with 4.9% revenue growth and margin expansion. Recent news highlights director share sales and mixed regional performance, particularly weakness in North America despite global strength.
CL offers stable dividend returns and consistent earnings but faces valuation concerns with a P/E of 36.34 and competitive pressures in key markets. Analyst consensus targets $99.10 with 42% buy ratings, suggesting moderate upside potential balanced against premium valuation and domestic market challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →
